Evidence map›Paper›PMID 28730526›Full record

ArticleCurrent rheumatology reports2017

Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment.

Hannah Cohen, Beverley J Hunt, Maria Efthymiou, Ian J Mackie, Munther Khamashta, David A Isenberg, RAPS Trial Investigators

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Current rheumatology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Hannah CohenDepartment of Haematology, University College London Hospitals NHS Foundation Trust, London, UK. hannah.cohen@ucl.ac.uk.
Beverley J HuntDepartment of Thrombosis and Haemophilia, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, UK.
Maria EfthymiouHaemostasis Research Unit, Department of Haematology, University College London, 51 Chenies Mews, London, WC1E 6HX, UK.
Ian J MackieHaemostasis Research Unit, Department of Haematology, University College London, 51 Chenies Mews, London, WC1E 6HX, UK.
Munther KhamashtaLupus Research Unit, Division of Women's Health, King's College London, London, UK.
David A IsenbergCentre for Rheumatology, Division of Medicine, University College London, London, UK.
RAPS Trial Investigators

Funding

Versus Arthritis 19708
6 · The paper itself

Abstract

We respond to comments by Dufrost et al. about the RAPS trial, in particular, showing that the trial did achieve its target sample size; pointing out that thrombin potential is not synonymous with overall thrombin generation; confirming that overall, no increased thrombotic risk was evident comparing rivaroxaban with warfarin; and that high-risk patients (28% were triple positive, representative of patients with venous thromboembolism requiring standard-intensity anticoagulation) were included; and clarifying our rationale for using a laboratory surrogate primary outcome measure instead of a clinical one.

Indexed as

Antiphospholipid SyndromeVenous ThromboembolismAnticoagulantsHumansRivaroxabanSystematic Reviews as TopicWarfarinAnticoagulantsRivaroxabanWarfarinAntiphospholipid syndromeRivaroxabanThrombin generationVenous thromboembolismWarfarin

Identifiers

PMID28730526
PMCPMC5519642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.